GlassScriptPhysician profile
Marc A Bodenheimer
NPI 1598747875
$6,665.43
in general payments reported to CMS, 2019-2025
28 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 83% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $438 · 2021: $582 · 2022: $862 · 2023: $788 · 2024: $1,496 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,057 · Honoraria: $25.59 · Gift: $14.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,057.25 |
| Honoraria | $25.59 |
| Gift | $14.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,333.42 | 2019-2025 | Clareon, Lensx, Rocklatan |
| Abbvie INC. | $870.98 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Tarsus Pharmaceuticals, INC. | $599.45 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $510.83 | 2021-2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $472.48 | 2020-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Rxsight INC | $433.55 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $288.65 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $247.56 | 2019-2025 | Cequa |
| Allergan, INC. | $238.64 | 2019-2022 | |
| Horizon Therapeutics Plc | $233.44 | 2020-2023 | Tepezza |
| Harrow Eye, LLC | $232.73 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $224.00 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $187.93 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $112.81 | 2022-2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Ivantis, INC | $111.36 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $96.62 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Ocular Therapeutix, INC. | $83.41 | 2022-2025 | Dextenza |
| Sight Sciences, INC. | $81.16 | 2022-2024 | Omni Surgical System |
| Dompe US, INC. | $57.68 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.33 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $46.03 | 2021 | |
| Shire North American Group INC | $33.04 | 2019 | |
| Glaukos Corporation | $30.39 | 2024 | Idose |
| New World Medical,INC. | $21.99 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Topcon Healthcare Solutions, INC. | $17.42 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.43 | 2021 | |
| Genentech USA, INC. | $15.65 | 2019 | |
| Integra Lifesciences Corporation | $13.45 | 2023 | Biodrestore, Medihoney, Biodfactor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Bodenheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.